---
title: "Weekly Recap | CRISPR Therap -4.12%, most brokers rate it buy"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/300187510.md"
description: "CRISPR Therapeutics (CRSP) fell 4.12% for the week to close at $54.23. The S&P 500 rose 1.21% over the same period, leaving the stock about 5.33 percentage points behind the benchmark. The week opened at $57.98 and climbed to an intraday high of $60.72 on Tuesday, before giving up the gains: Wednesday’s low dropped to $54.67, and the stock traded between $53.79 and $57.17 over Thursday and Friday before settling near the week’s low."
datetime: "2026-09-26T06:12:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/300187510.md)
  - [en](https://longbridge.com/en/news/300187510.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/300187510.md)
generator: "portal-rs"
---

# Weekly Recap | CRISPR Therap -4.12%, most brokers rate it buy

## The Week

CRISPR Therapeutics (CRSP) fell 4.12% for the week to close at $54.23. The S&P 500 rose 1.21% over the same period, leaving the stock about 5.33 percentage points behind the benchmark. The week opened at $57.98 and climbed to an intraday high of $60.72 on Tuesday, before giving up the gains: Wednesday’s low dropped to $54.67, and the stock traded between $53.79 and $57.17 over Thursday and Friday before settling near the week’s low.

## Key Events

Two threads ran through the week. Early on, commentary revisited whether CRISPR Therapeutics remains attractive after a rocky 2026. At the same time, insider sales drew attention: director Ali Behbahani disposed of about $780.6k of common shares, and general counsel James R. Kasinger disposed of about $626.5k worth later in the week. The other driver came from the industry: Anthropic’s biolab announced a discovery it compared to CRISPR, and gene editing stocks fell in response, with CRSP losing ground on Wednesday and Thursday.

## Analyst Ratings

Of the 22 analysts covering the stock, 8 rate it buy, 5 rate it overweight and 9 rate it hold, with no underweight or sell ratings. The consensus rating is buy, and the consensus target of $87.55556 sits about 61.45% above the $54.23 close. The target range of $44 to $291 shows wide disagreement, and within the biotech industry the stock ranks 21st by rating strength.

## The Week Ahead

The macro calendar is full next week: the Dallas Fed manufacturing index on Monday, followed on Tuesday by FHFA house prices, the Case-Shiller 20-city index, JOLTS job openings and the consumer confidence index. These data points can shift risk appetite for long-duration assets like biotech, so they are worth watching for sector-wide direction.

## In Short

This week mixed price action with a still-favourable rating picture. The stock lagged the market and weakened into the close, while the consensus rating remained buy and the consensus target was more than 60% above spot. On the latest trading day, small and medium orders showed clear net selling while large orders were moderately net buying. What comes next depends on how macro data affect risk appetite and whether insider selling continues to press the stock.

*This article is generated by LongbridgeAI from market data, for information only and not investment advice.*

### Related Stocks

- [CRSP.US](https://longbridge.com/en/quote/CRSP.US.md)

## Related News & Research

- [CRISPR Therapeutics (CRSP) Could Be 38% Undervalued As CASGEVY Expansion Draws Focus](https://longbridge.com/en/news/300450341.md)
- [Why CRISPR Therapeutics (CRSP) Is Back In The Spotlight](https://longbridge.com/en/news/299579710.md)
- [‘Open Your Eyes,’ Says Top Investor About Oracle Stock](https://longbridge.com/en/news/301160283.md)
- [Marvell Now Sees as Much as $90 Billion in Annual Sales by Fiscal 2031. Here's Why It's a Chip Stock to Buy.](https://longbridge.com/en/news/301114413.md)
- [Palantir vs. Oracle – Why Daniel Ives Says Buy One, Hold the Other](https://longbridge.com/en/news/301155464.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**